2022-07-28| Special

BIO Asia-Taiwan 2022: Looking for the Exit; Startup Considerations and Strategies

by Reed Slater
Share To

Hundreds of biotech startups pop up yearly, and their fate typically has three options. They can flourish into successful independent companies of their own, shrink and shutter in failure, or, most likely, make an exit through a merger or acquisition to a larger company. 

Timothy K. Lu, Co-founder, and CEO of Senti Biosciences, Inc., moderated the panel “Exit Strategies for Early Stage New Drug Companies” at BIO Asia-Taiwan 2022, which began July 27 with the theme of “Connecting the Asian Value Chain.” The event brings together biotechnology, pharmaceutical executives, and investors worldwide to explore business opportunities in Taiwan’s emerging biotech sector. 

During the panel, five respected industry experts provided their thoughts on startup exit strategies and the considerations for maneuvering within the biotech industry. The panelists issued their opinions on the importance of an initial plan when starting a company, the opportunities and limitations of cross-border investments, and sufficient international patent protection in a globalized world. 

It's free! Log in now to read

NDA for Biogen-Sage’s Zuranolone Accepted by FDA, Marking Another Step Forward in Depression Drug Development
BMS Returns $475 Million Cancer Asset To Dragonfly Therapeutics
FDA Expands Approval For Takeda’s Takhzyro To Prevent Hereditary Angioedema Attacks
Abbott’s New Technologies for Arrhythmia Treatment Secure FDA and European Approval
First Human Trial for Marburg Virus Vaccine Reports Success
Karuna Licenses Goldfinch’s Mood Disorder Candidates For Potential $535 Million
Novel Bioengineered Wearable Edgeless Skin Brings Hope to Revolutionize Plastic and Reconstructive Surgery
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!